Patents by Inventor Yushma BHURRUTH-ALCOR

Yushma BHURRUTH-ALCOR has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted pyrazolo[3,4-d]pyrimidines as mTOR inhibitors
    Patent number: 11731973
    Abstract: The invention relates to novel mTOR inhibitor compounds having the formula (I) or a pharmaceutically acceptable salt thereof, compositions comprising the mTOR inhibitor compounds, methods for producing the same, and the use thereof.
    Type: Grant
    Filed: June 19, 2020
    Date of Patent: August 22, 2023
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Laurence Clary, Jean-François Fournier, Gilles Ouvry, Yushma Bhurruth-Alcor, Etienne Thoreau, Loïc Tomas
  • CANCER TREATMENTS TARGETING CANCER STEM CELLS
    Publication number: 20230023124
    Abstract: Disclosed are compounds, methods, compositions, uses, and kits that allow for treating cancer. In some embodiments, the compounds are used to treat diseases or disorders. The compounds may treat cancer by targeting cancer stem cells. In some embodiments, the cancer is colorectal cancer, gastric cancer, gastrointestinal stromal tumor, ovarian cancer, lung cancer, breast cancer, pancreatic cancer, prostate cancer, testicular cancer, lymphoma, liver cancer, endometrial cancer, leukemia, or multiple myeloma. Disclosed are compounds, methods, compositions, uses, and kits that may be used in regenerative medicine. The compounds utilized in the disclosure are of Formula (0) and (I).
    Type: Application
    Filed: November 6, 2020
    Publication date: January 26, 2023
    Applicant: Remedy Plan, Inc.
    Inventors: Yushma Bhurruth-Alcor, Gregory Thomas Crimmins, Dennise Alexandra De Jesús Diaz, Caroline Mae Robb
  • MTOR inhibitor compounds
    Patent number: 11518767
    Abstract: The invention relates to novel mTOR inhibitor compounds having the general formula (I), to compositions comprising said mTOR inhibitor compounds, methods for producing same, and the use thereof in compositions as a drug.
    Type: Grant
    Filed: June 19, 2020
    Date of Patent: December 6, 2022
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Laurence Clary, Jean-François Fournier, Gilles Ouvry, Yushma Bhurruth-Alcor, Etienne Thoreau, Loïc Tomas
  • CANCER TREATMENTS TARGETING CANCER STEM CELLS
    Publication number: 20220324842
    Abstract: Disclosed are compounds, methods, compositions, and kits that allow for treating cancer by, e.g., targeting cancer stem cells. In some embodiments, the cancer is colorectal cancer, gastric cancer, gastrointestinal stromal tumor, ovarian cancer, lung cancer, breast cancer, pancreatic cancer, prostate cancer, testicular cancer, or lymphoma. In some embodiments, the cancer is liver cancer, endometrial cancer, leukemia, or multiple myeloma.
    Type: Application
    Filed: May 3, 2019
    Publication date: October 13, 2022
    Applicant: Remedy Plan, Inc.
    Inventors: Gregory Thomas Crimmins, Dennise Alexandra De Jesús Diaz, Yushma Bhurruth-Alcor
  • NOVEL MTOR INHIBITOR COMPOUNDS
    Publication number: 20200317679
    Abstract: The invention relates to novel mTOR inhibitor compounds. The invention is characterized in that the mTOR inhibitor compounds have general formula (I). The invention also relates to compositions comprising said mTOR inhibitor compounds, methods for producing same, and the use thereof in compositions as a drug.
    Type: Application
    Filed: June 19, 2020
    Publication date: October 8, 2020
    Inventors: Laurence CLARY, Jean-François FOURNIER, Gilles OUVRY, Yushma BHURRUTH-ALCOR, Etienne THOREAU, Loïc TOMAS
  • MTOR INHIBITOR COMPOUNDS
    Publication number: 20200317683
    Abstract: The invention relates to novel mTOR inhibitor compounds. The invention is characterized in that the mTOR inhibitor compounds have general formula (I). The invention also relates to compositions comprising said mTOR inhibitor compounds, methods for producing same, and the use thereof in compositions as a drug.
    Type: Application
    Filed: June 19, 2020
    Publication date: October 8, 2020
    Inventors: Laurence CLARY, Jean-François FOURNIER, Gilles OUVRY, Yushma BHURRUTH-ALCOR, Etienne THOREAU, Loïc TOMAS
  • Chemokine CXCR1 and CXCR2 receptor antagonist compounds, and use thereof in the treatment of chemokine-mediated pathologies
    Patent number: 10647706
    Abstract: Novel chemokine CXCR1 and CXCR2 receptor antagonist compounds of general formula (I) are described. Also described, are pharmaceutical compositions including the compounds, and use of the compounds and the compositions for the treatment of chemokine-mediated pathologies, more specifically in the field of dermatology.
    Type: Grant
    Filed: April 2, 2019
    Date of Patent: May 12, 2020
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Branislav Musicki, Yushma Bhurruth-Alcor
  • Benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine and cosmetics
    Patent number: 10556883
    Abstract: Compounds having formula (I) are described. Also described, are methods of using these compounds to treat diseases, conditions, and disorders.
    Type: Grant
    Filed: February 1, 2017
    Date of Patent: February 11, 2020
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Gilles Ouvry, Craig Steven Harris, Yushma Bhurruth-Alcor
  • NOVEL CHEMOKINE CXCR1 AND CXCR2 RECEPTOR ANTAGONIST COMPOUNDS, AND USE THEREOF IN THE TREATMENT OF CHEMOKINE-MEDIATED PATHOLOGIES
    Publication number: 20190225598
    Abstract: Novel chemokine CXCR1 and CXCR2 receptor antagonist compounds of general formula (I) are described. Also described, are pharmaceutical compositions including the compounds, and use of the compounds and the compositions for the treatment of chemokine-mediated pathologies, more specifically in the field of dermatology.
    Type: Application
    Filed: April 2, 2019
    Publication date: July 25, 2019
    Applicant: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Branislav MUSICKI, Yushma BHURRUTH-ALCOR
  • Chemokine CXCR1 and CXCR2 receptor antagonist compounds, and use thereof in the treatment of chemokine-mediated pathologies
    Patent number: 10287278
    Abstract: Novel chemokine CXCR1 and CXCR2 receptor antagonist compounds of general formula (I) are described. Also described, are pharmaceutical compositions including the compounds, and use of the compounds and the compositions for the treatment of chemokine-mediated pathologies, more specifically in the field of dermatology.
    Type: Grant
    Filed: December 22, 2015
    Date of Patent: May 14, 2019
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Branislav Musicki, Yushma Bhurruth-Alcor
  • NOVEL CHEMOKINE CXCR1 AND CXCR2 RECEPTOR ANTAGONIST COMPOUNDS, AND USE THEREOF IN THE TREATMENT OF CHEMOKINE-MEDIATED PATHOLOGIES
    Publication number: 20170349575
    Abstract: Novel chemokine CXCR1 and CXCR2 receptor antagonist compounds of general formula (I) are described. Also described, are pharmaceutical compositions including the compounds, and use of the compounds and the compositions for the treatment of chemokine-mediated pathologies, more specifically in the field of dermatology.
    Type: Application
    Filed: December 22, 2015
    Publication date: December 7, 2017
    Inventors: Branislav MUSICKI, Yushma BHURRUTH-ALCOR
  • BENZENESULFONAMIDE COMPOUNDS, METHOD FOR SYNTHESIZING SAME, AND USE THEREOF IN MEDICINE AND COSMETICS
    Publication number: 20170247353
    Abstract: Compounds having formula (I) are described. Also described, are methods of using these compounds to treat diseases, conditions, and disorders.
    Type: Application
    Filed: February 1, 2017
    Publication date: August 31, 2017
    Inventors: Gilles OUVRY, Craig Steven HARRIS, Yushma BHURRUTH-ALCOR